**MS in the 21st Century Mapping Study to Quantify the Educational Offerings for Patients from Multiple Stakeholders in the Field of Multiple Sclerosis in Europe and Canada**

Peter Rieckmann¹, MD on behalf of the Merck *MS in the 21st Century* initiative and Dr Elisabetta Verdun Di Cantogno², MD, PhD

¹Schoenstatt Bamberg Hospital, Bamberg, Germany; ²Ares Trading S.A. – an affiliate of Merck Serono S.A.

**BACKGROUND**

- In 2011, led by a steering group of international multiple sclerosis (MS) specialists, the MS is the 21st Century initiative was formed.
- In 2016, the group took a revised approach and expanded to include a group of patient representatives to incorporate the patient perspective.
- The group’s current focus is to increase collaboration, education and communication between clinicians and people with MS (PwMS).
- To explore the development of educational resources, the steering group decided to capture the existing educational offerings for PwMS.

**OBJECTIVE**

- The mapping exercise aimed to better understand the diversity and number of patient educational materials available for PwMS across Europe and Canada provided by a broad range of stakeholders involved in the care and education of PwMS.
- This research model will be applied to other global regions.

**METHODS**

- Educational resources in Europe and Canada were recorded using pre-defined mapping parameters (Figure 1).

**RESULTS**

**Resource review**

- From the 21 countries mapped, 1,657 different educational resources were identified across all stakeholders, which included webcasts and online materials, books, and patient videos. Grading social needs resources, a total of 1,672 resources were further analyzed.
- The group also considered:
  - How the resources were disseminated to PwMS
  - How the resources were distributed across country and stakeholder
  - How the resources were disseminated to PwMS

**Resource dissemination**

- Websites and online content were the most common formats, followed by booklets/leaflets and brochures (Figure 6).
- When looking at resource format breakdown by country, website content was most common for the UK and help and advice whereas booklets and leaflets were more common for Germany.

**CONCLUSIONS**

- This study demonstrated that there is a range of educational materials for PwMS but the type and number of resources varies between countries.
- Most materials were accessed through patient associations, although pharmaceutical companies also contributed.
- There was a good offering of general information, but MS for PwMS is lacking.
- There is a lack of guidance for specific stages of disease, particularly disease progression and later stages of MS.
- Few online focused or patient and HCP perceived, with no active identifiers on joint educational programmes focused on improving interaction in a consultation setting.

**ACKNOWLEDGEMENTS**

The MS in the 21st Century initiative is financially supported equally by Merck KGaA, Darmstadt, Germany, Schering Aktiengesellschaft and by the MS research community, which includes financial support from several organisations. The presenters of this poster are experienced for this purpose.

**DISCLOSURES**

Peter Rieckmann receives honorarium from: Astellas, AstraZeneca, Baxter, Bayer, BMS, BMS, Sanofi, Genzyme, Johnson & Johnson, MSD, Merck, Novartis, Roche, Genentech, TEVA, and uniQure. He also received research grants from: Amgen, Aprels, Sanofi, Novartis, Teva, MS Society of America, Canadian MS Society, Multiple Sclerosis Research Canada, and National Institute of Neurological Disorders and Stroke. He has received personal compensation from: Abbott, AstraZeneca, Bayer, Genzyme, Merck, Novartis, Teva, German Multiple Sclerosis Society, and Merck KGaA, Darmstadt, Germany as an employee of Merck KGaA.